Melinta names Sue Cammarata CMO
This article was originally published in Scrip
Executive Summary
Antibiotic developer Melinta Therapeutics has appointed Dr Sue Cammarata chief medical officer. Dr Cammarata will be responsible for managing the global development and registration strategy for Melinta's product candidates, including delafloxacin, which is currently being investigated in Phase III for the treatment of acute bacterial skin and skin structure infections. She previously served as vice-president of clinical research at Shire, and before that worked at Novartis.